[1]
|
Vilahur, G., et al. (2014) The Burden of Cardiovascular Risk Factors and Coronary Heart Disease in Europe and Worldwide. European Heart Journal Supplements, 16, A7-A11.
|
[2]
|
Hasan, I., Rashid, T. and Bhuiyan, M.H.U.R. (2015) PCI in Post Thrombolysis Stable STEMI Patients: A Timeline in Question. World Journal of Cardiovascular Diseases, 5, 335-342. http://dx.doi.org/10.4236/wjcd.2015.512039
|
[3]
|
Heidenreich, P.A., et al. (2011) Forecasting the Future of Cardiovascular Disease in the United States a Policy Statement from the American Heart Association. Circulation, 123, 933-944.
http://dx.doi.org/10.1161/CIR.0b013e31820a55f5
|
[4]
|
Hasan, I., Rashid, T. and Bhuiyan, M.H.U.R. (2015) Routine Primary PCI; Whether and When Necessary for the Management of NSTEMI—An Evidence Based Evaluation. World Journal of Cardiovascular Diseases, 5, 343-350.
http://dx.doi.org/10.4236/wjcd.2015.512040
|
[5]
|
Mendis, S., Puska, P. and Norrving, B. (2011) Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization.
|
[6]
|
World Heart Foundation (2014) Quick Facts on Cholesterol/Lipids.
http://www.world-heart-federation.org/press/fact-sheets/cardiovascular-disease-risk-factors/quick-facts-on-cholesterollipids/
|
[7]
|
Huang, J.C. and Hoogwerf, B.J. (2005) Cholesterol Guidelines Update: More Aggressive Therapy for Higher-Risk Patients. Cleveland Clinic Journal of Medicine, 72, 253-262.
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/heart-disease-risk-reduction/
|
[8]
|
Schachter, M. (2005) Chemical, Pharmacokinetic and Pharmacodynamic Properties of Statins: An Update. Fundamental & Clinical Pharmacology, 19, 117-125. http://dx.doi.org/10.1111/j.1472-8206.2004.00299.x
|
[9]
|
Jed, D. (2014) Statins: Mechanism of Action.
https://www.atrainceu.com/course-module/1473410-76_statins-controlling-cholesterol-module-2
|
[10]
|
Kini, A.S., et al. (2013) Changes in Plaque Lipid Content after Short-Term Intensive versus Standard Statin Therapy: The Yellow Trial (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy). Journal of the American College of Cardiology, 62, 21-29. http://dx.doi.org/10.1016/j.jacc.2013.03.058
|
[11]
|
Tawakol, A., Fayad, Z.A., Mogg, R., Alon, A., Klimas, M.T., Dansky, H., et al. (2013) Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation Results of a Multicenter Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Feasibility Study. Journal of the American College of Cardiology, 62, 909-917. http://dx.doi.org/10.1016/j.jacc.2013.04.066
|
[12]
|
Nozue, T., Yamamoto, S., Tohyama, S., Fukui, K., Umezawa, S., Onishi, Y., et al. (2012) Comparison of Arterial Remodeling and Changes in Plaque Composition between Patients with Progression versus Regression of Coronary Atherosclerosis during Statin Therapy (from the TRUTH Study). The American Journal of Cardiology, 109, 1247-1253. http://dx.doi.org/10.1016/j.amjcard.2011.12.016
|
[13]
|
Kashani, A., Phillips, C.O., Foody, J.M., Wang, Y., Mangalmurti, S., Ko, D.T. and Krumholz, H.M. (2006) Risks Associated with Statin Therapy a Systematic Overview of Randomized Clinical Trials. Circulation, 114, 2788-2797.
http://dx.doi.org/10.1161/circulationaha.106.624890
|
[14]
|
FDA (2014) FDA Expands Advice on Statin Risks.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm
|
[15]
|
Tobert, J.A. (2003) Lovastatin and beyond: The History of the HMG-CoA Reductase Inhibitors. Nature Reviews Drug Discovery, 2, 517-526. http://dx.doi.org/10.1038/nrd1112
|
[16]
|
Akira, E. (2010) A Historical Perspective on the Discovery of Statins. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 86, 484-493. http://dx.doi.org/10.2183/pjab.86.484
|
[17]
|
Tunstall-Pedoe, H. (2013) Starting Statins for Primary Prevention of Cardiovascular Disease. Heart, 99, 1547-1548.
http://dx.doi.org/10.1136/heartjnl-2013-304284
|
[18]
|
Reiner, Z., Catapano, A.L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., et al., The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista Española de Cardiología (English Edition), 64, 1168. http://dx.doi.org/10.1016/j.rec.2011.09.015
|
[19]
|
Ray, K.K., Kastelein, J.J.P., Boekholdt, S.M., Nicholls, S.J., Khaw, K.-T., Ballantyne, C.M., et al. (2014) The ACC/AHA 2013 Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: The Good the Bad and the Uncertain: A Comparison with ESC/EAS Guidelines for the Management of Dyslipidaemias 2011. European Heart Journal, 35, 960-968. http://dx.doi.org/10.1093/eurheartj/ehu107
|
[20]
|
Smith, S.C. and Grundy, S.M. (2014) 2013 ACC/AHA Guideline Recommends Fixed-Dose Strategies Instead of Targeted Goals to Lower Blood Cholesterol. Journal of the American College of Cardiology, 64, 601-612.
http://dx.doi.org/10.1016/j.jacc.2014.06.1159
|
[21]
|
Barkas, F., Milionis, H., Kostapanos, M.S., Mikhailidis, D.P., Elisaf, M. and Liberopoulos, E. (2015) How Effective Are the ESC/EAS and 2013 ACC/AHA Guidelines in Treating Dyslipidemia? Lessons from a Lipid Clinic. Current Medical Research & Opinion, 31, 221-228.
|
[22]
|
Taylor, F., Huffman, M.D., Macedo, A.F., Moore, T.H.M., Burke, M., Smith, G.D., et al. (2013) Statins for the Primary Prevention of Cardiovascular Disease. Cochrane Database of Systematic Reviews, 1, CD004816.
http://dx.doi.org/10.1002/14651858.cd004816.pub5
|
[23]
|
Brugts, J., Yetgin, T., Hoeks, S.E., Gotto, A.M., Shepherd, J., Westendorp, R.G., et al. (2009) The Benefits of Statins in People without Established Cardiovascular Disease but with Cardiovascular Risk Factors: Meta-Analysis of Randomised Controlled Trials. BMJ, 338, b2376.
|
[24]
|
Mills, E.J., Rachlis, B., Wu, P., Devereaux, P.J., Arora, P. and Perri, D. (2008) Primary Prevention of Cardiovascular Mortality and Events with Statin Treatments: A Network Meta-Analysis Involving More than 65,000 Patients. Journal of the American College of Cardiology, 52, 1769-1781. http://dx.doi.org/10.1016/j.jacc.2008.08.039
|
[25]
|
Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., et al. (2006) Primary Prevention of Cardiovascular Disease with Pravastatin in Japan (MEGA Study): A Prospective Randomised Controlled Trial. The Lancet, 368, 1155-1163. http://dx.doi.org/10.1016/S0140-6736(06)69472-5
|
[26]
|
Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., et al. (1998) Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of AFCAPS/ TexCAPS. JAMA, 279, 1615-1622. http://dx.doi.org/10.1001/jama.279.20.1615
|
[27]
|
Ridker, P.M., Danielson, E., Fonseca, F.A.H., Genest, J., Gotto Jr., A.M., Kastelein, J.J.P., et al. (2009) Reduction in C-Reactive Protein and LDL Cholesterol and Cardiovascular Event Rates after Initiation of Rosuvastatin: A Prospective Study of the JUPITER Trial. The Lancet, 373, 1175-1182. http://dx.doi.org/10.1016/S0140-6736(09)60447-5
|
[28]
|
Knopp, R.H., d’Emden, M., Smilde, J.G., Pocock, S.J. and on behalf of the ASPEN Study Group (2006) Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects with Type 2 Diabetes the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care, 29, 1478-1485. http://dx.doi.org/10.2337/dc05-2415
|
[29]
|
Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A.W., Livingstone, S.J., et al. (2004) Primary Prevention of Cardiovascular Disease with Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo-Controlled Trial. The Lancet, 364, 685-696.
http://dx.doi.org/10.1016/S0140-6736(04)16895-5
|
[30]
|
Fellström, B.C., Jardine, A.G., Schmieder, R.E., Holdaas, H., Bannister, K., Beutler, J., et al. (2009) Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine, 360, 1395-1407.
http://dx.doi.org/10.1056/NEJMoa0810177
|
[31]
|
Mizuno, K., Nakaya, N., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., et al. (2008) Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study). Circulation, 117, 494-502.
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.671826
|
[32]
|
Robinson, J.G. (2014) Starting Primary Prevention Earlier with Statins. The American Journal of Cardiology, 114, 1437-1442. http://dx.doi.org/10.1016/j.amjcard.2014.07.076
|
[33]
|
Sever, P.S., Chang, C.L., Gupta, A.K., Whitehouse, A. and Poulter, N.R. (2011) The Anglo-Scandinavian Cardiac Outcomes Trial: 11-Year Mortality Follow-Up of the lipid-Lowering Arm in the UK. European Heart Journal, 32, 2525-2532. http://dx.doi.org/10.1093/eurheartj/ehr333
|
[34]
|
Pletcher, M.J., Lazar, L., Bibbins-Domingo, K., Moran, A., Rodondi, N., Coxson, P., et al. (2009) Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering. Annals of Internal Medicine, 150, 243-254. http://dx.doi.org/10.7326/0003-4819-150-4-200902170-00005
|
[35]
|
Grabowski, D.C., Lakdawalla, D.N., Goldman, D.P., Eber, M., Liu, L.Z., Abdelgawad, T., et al. (2012) The Large Social Value Resulting from Use of Statins Warrants Steps to Improve Adherence and Broaden Treatment. Health Affairs, 31, 2276-2285. http://dx.doi.org/10.1377/hlthaff.2011.1120
|
[36]
|
Ridker, P.M. (2003) Rosuvastatin in the Primary Prevention of Cardiovascular Disease among Patients with Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein Rationale and Design of the JUPITER Trial. Circulation, 108, 2292-2297. http://dx.doi.org/10.1161/01.CIR.0000100688.17280.E6
|
[37]
|
Ridker, P.M., Rifai, N., Clearfield, M., Downs, J.R., Weis, S.E., Miles, J.S., et al. (2001) Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events. New England Journal of Medicine, 344, 1959-1965. http://dx.doi.org/10.1056/NEJM200106283442601
|
[38]
|
Ray, K.K., Seshasai, S.R.K., Erqou, S., Sever, P., Jukema, J.W., Ford, I. and Sattar, N. (2010) Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-Analysis of 11 Randomized Controlled Trials Involving 65 229 Participants. Archives of Internal Medicine, 170, 1024-1031. http://dx.doi.org/10.1001/archinternmed.2010.182
|
[39]
|
Hajar, R. (2011) Statins: Past and Present. Heart Views, 12, 121-127. http://dx.doi.org/10.4103/1995-705X.95070
|
[40]
|
Unal, B., Critchley, J.A. and Capewell, S. (2005) Modelling the Decline in Coronary Heart Disease Deaths in England and Wales, 1981-2000: Comparing Contributions from Primary Prevention and Secondary Prevention. BMJ, 331, 614.
http://dx.doi.org/10.1136/bmj.38561.633345.8F
|
[41]
|
Jamroz-Wisniewska, A. and Beltowski, J. (2005) Adverse Effects of Statins. International Journal of Pharmacology, 1, 210-225. http://dx.doi.org/10.3923/ijp.2005.210.225
|
[42]
|
Tocci, G., Francione, V., Sciarretta, S. and Volpe, M. (2005) Adverse Effects of Statins. High Blood Pressure & Cardiovascular Prevention, 12, 141-148. http://dx.doi.org/10.2165/00151642-200512030-00005
|
[43]
|
Owen, A. (2007) How Should the Efficacy of Novel Treatments Be Assessed in Survival Trials? International Journal of Cardiology, 120, 297-300. http://dx.doi.org/10.1016/j.ijcard.2006.11.232
|